The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 dose-expansion study of oral TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with Ewing sarcoma (EWS).
 
Gregory Michael Cote
Consulting or Advisory Role - BioAtla; C4 Therapeutics; Daiichi Sankyo/UCB Japan; Eisai; Foghorn Therapeutics; Ikena Oncology
Research Funding - Agios (Inst); Bavarian Nordic; Bayer (Inst); BioAtla (Inst); C4 Therapeutics (Inst); CBA Research (Inst); Eisai (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); Ikena Oncology (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Rain Therapeutics (Inst); Repare Therapeutics (Inst); Servier (Inst); Springworks Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
 
Andrew J. Wagner
Consulting or Advisory Role - AADi; BioAtla; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; InhibRx; Lilly; Mundipharma; SERVIER
Research Funding - AADi (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst); Rain Therapeutics (Inst)
 
John A. Charlson
Consulting or Advisory Role - Adaptimmune; Deciphera
Research Funding - Lilly (Inst)
 
James S Hu
No Relationships to Disclose
 
Mark Andrew Dickson
Research Funding - AADi (Inst); Lilly (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
 
Gina Z. D'Amato
Consulting or Advisory Role - Blueprint Medicines; Daiichi Sankyo/Lilly; Deciphera; Epizyme
 
Sujan Kabir
Employment - Sumitomo Pharma Oncology
 
Bo Xu
Employment - Sumitomo Pharma Oncology
 
Claudia Lebedinsky
Employment - Sumitomo Dainnipon Pharma Oncology
Patents, Royalties, Other Intellectual Property - US patent application submitted, title: Methods of treating myeloproliferative neoplasms. Pending patent.
 
Margaret von Mehren
Honoraria - Boehringer Ingelheim; Deciphera; Molleculin
Consulting or Advisory Role - deciphera; GlaxoSmithKline
Research Funding - ASCO (Inst); Deciphera (Inst); Gradalis (Inst); Novartis (Inst); Solaris Health (Inst); Sumitomo Pharma Oncology (Inst); Theseus (Inst)
Patents, Royalties, Other Intellectual Property - cell line
Travel, Accommodations, Expenses - Boehringer Ingelheim
Other Relationship - NCCN